8:00 am Registration & Morning Coffee

8:55 am Chair’s Opening Remarks

Discovering Functional Biomarkers to Identify Combination Therapies for Subtype-Driven Drug Development

9:00 am Utilising Prognosis Biomarkers to Understand the Mechanisms Underpinning IBD to Better Manage the Disease

  • Towia Libermann Associate Professor of Medicine, Beth Israel Deaconess Medical Centre & Harvard Medical School


  • Can we use multi-omics data to identify novel biomarkers that predict flares of symptoms be used to understand key components of the disease?
  • The use of biomarkers for IBD to further stratify patients and tailor their treatment plan
  • Can biomarkers that predict treatment response also be used to understand key mechanisms involved in various symptoms of IBD?

9:30 am Panel Discussion – Improving the Understanding of IBD Patient Subtype to Permit Bespoke Treatment Options

  • Nicole Desch Associate Director, GI Drug Discovery, Takeda
  • Suryasarathi Dasgupta Associate Director - Precision Medicine & Immunology, AbbVie
  • Bradford McRae Senior Director of Translational Science, Janssen Pharmaceuticals of Johnson & Johnson


  • What procedure can we implement to successfully standardize and identify novel biomarkers that are associated with specific patient subtypes?
  • How can we develop companion diagnostics that align with the unique characteristics of each patient subtype to personalize their IBD treatment journey?
  • Assessing how patient subtype understanding can permit increased drug response rate
  • Exploring the potential for patient subtype-driven drug development to enhance treatment outcomes and reduce adverse effects

10:30 am Morning Refreshments & Speed Networking


As the precision medicine in IBD community is reunited, this valuable session will ensure you can reconnect with your peers in the room to make new and lasting connections. All attendees will have the opportunity to meet and network with their academic and industry equals.

Overcome IBD Heterogeneity with Novel Biomarkers for Better Patient Stratification

11:30 am Effective Patient Stratification is Necessary to Develop Biomarkers & Improve Drug Response Rate

  • Ben Kostiuk Associate Director of Life Science Partnerships, Crohn’s & Colitis Foundation


  • Empowering insights into stratification of patients based on treatment response to provide informed treatment strategies
  • Exploring strategies of using this information further understand IBD heterogeneity and treatment of choice

12:00 pm Unleashing Synergy: The Power of Combination Therapies to Tackle Treatment Failure

  • Jan Wehkamp Vice President & Gastroenterology Disease Area Stronghold Lead, Immunology, Janssen Pharmaceuticals, Johnson & Johnson


  • Optimizing patient stratification to aid in identifying the right combination therapies for IBD patients who have not responded well to single treatments
  • What is necessary for biomarkers to help in identifying which combination therapies are most likely to be effective for individual IBD patients?
  • How can precision medicine assist in optimizing the balance between effectiveness and safety when combining treatments? 

12:30 pm Lunch & Networking Break

Boosting Prognosis Accuracy to Forecast Patient Disease State for Improved Clinical Trial Design

1:30 pm Identifying Prognostic Biomarkers for IBD: A Roadmap to Improved Prediction for Disease State

  • Scott Snapper Director, Inflammatory Bowel Disease Center, Boston Children’s Hospital


  • Techniques for utilizing a multi-omics approach to identify prognostic biomarkers and predict disease-course severity for patients?
  • Should we be considering implementing patient stratification to predict the prognosis of patients?

2:00 pm “A Picture is Worth a Million Data Points” Novel H&E Image-Based, AI-Assisted Quantification of Epithelial Defects for Predicting IBD Therapy Response

  • Thaddeus Stappenbeck Cleveland Clinic Department Chair, Inflammation & Immunity, Founder, Mobius Care


  • We know multiomics studies have pointed to several epithelial defects in IBD, even in non-lesional/inflamed areas of the gut
  • These defects result from multiple inputs from the host and environment and are poised to synthesize complex multiomics data
  • We have developed AI-assisted image-based analyses to provide quantitative information that correlates with patient outcomes such as therapeutic response

2:10 pm Roundtable Discussion – Understanding the Link Between Prognosis, Patient Stratification & Monitoring

  • Towia Libermann Associate Professor of Medicine, Beth Israel Deaconess Medical Centre & Harvard Medical School


  • What are the necessary steps before we can accurately stratify patients based on their predicted disease course?
  • Is it possible to stratify patients based on monitoring drug response rate?
  • What are we missing as we strive towards harnessing prognostic data for a precision-based therapies?
  • What is needed to derive at clinically relevant and clinically useful biomarkers?
  • How can we harness data predicting disease course to predict drug response?
  • Can we use a multi-factorial approach to embrace data on prognosis, stratification and monitoring to accelerate clinical trial design and improve clinical outcomes?

3:10 pm Afternoon Networking Break & Poster Session

Expedite Microbiome Profiling to Refine Treatment Options with Better Biomarkers for IBD

4:00 pm Microbiome-Based Tailored IBD Interventions for More Efficacious Therapy

  • Amanda Prince Associate Director - Immunology, Vedanta Biosciences


  • Overview of defined bacterial consortia as a microbiome therapeutic
  • Role for the microbiome in IBD
  • Overview of VE202 and preclinical work in IBD
  • Considering the need for personalised medicine – can we target multiple mechanisms simultaneously by harnessing the microbiome?

4:30 pm Biomarkers of Microbiome Disruption for Patient Stratification in Clinical Trials of Microbiome Therapeutics in IBD

  • Elizabeth Halvorsen Senior Director, Experimental and Translational Biology, Seres Therapeutics


  • Microbiome heterogeneity in structural, functional, and immuno-modulatory properties in IBD
  • Baseline biomarkers predictive of microbiome therapeutic pharmacodynamics in IBD
  • Relating microbiome disruption and immuno-modulatory properties to inform patient stratification

5:00 pm Chair’s Closing Remarks & End of Conference Day One